Adamchak Mark 4

What Happened
Mark Adamchak, Principal Accounting Officer of Bionano Genomics (BNGO), was granted a derivative award on 2026-02-02 covering 10,890 shares. The Form 4 lists the acquisition amount as $0.00 (derivative), and the filing reports a grant/award rather than a purchase or sale — no shares were sold or exercised.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (appears timely).
• Award type: Reported as a derivative grant (option); 10,890 shares listed; acquisition amount shown as $0.00.
• Vesting: Footnote states 100% of the shares subject to the option vest on the one-year anniversary of the grant date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication of immediate exercise or sale in this filing.

Context
This was a grant of an option-like award, not an open-market purchase or sale. Such awards give the insider the right to acquire shares in the future (subject to vesting and any exercise price) and do not by themselves signal immediate buying or selling pressure.